Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nils Florian Trautwein

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Frontiers in Medicine|June 26, 2023
Long-term prognostic factors for PRRT in neuroendocrine tumorsNils Florian Trautwein, Johannes Schwenck, Johann Jacoby, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 15, 2022
First-in-Humans PET/MRI of In Vivo GD2 Expression in OsteosarcomaNils Florian Trautwein, Gerald Reischl, Christian Seitz, et al.
Clinical Nuclear Medicine|January 25, 2024
Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot StudyNils Florian Trautwein, Clemens Hinterleitner, Lena Sophie Kiefer, et al.
Theranostics|February 7, 2024
A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [<sup>64</sup>Cu]Cu-NOTA-ch14.18/CHONils Florian Trautwein, Johannes Schwenck, Christian Seitz, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Frontiers in Medicine|June 26, 2023
Long-term prognostic factors for PRRT in neuroendocrine tumorsNils Florian Trautwein, Johannes Schwenck, Johann Jacoby, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 15, 2022
First-in-Humans PET/MRI of In Vivo GD2 Expression in OsteosarcomaNils Florian Trautwein, Gerald Reischl, Christian Seitz, et al.
Clinical Nuclear Medicine|January 25, 2024
Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot StudyNils Florian Trautwein, Clemens Hinterleitner, Lena Sophie Kiefer, et al.
Theranostics|February 7, 2024
A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [<sup>64</sup>Cu]Cu-NOTA-ch14.18/CHONils Florian Trautwein, Johannes Schwenck, Christian Seitz, et al.
Pageof 1